Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor
- 26 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 113 (6), 1-8
- https://doi.org/10.1007/s12185-021-03108-8
Abstract
Emicizumab reduces bleeding in hemophilia A patients with inhibitor (HA-inh). A combination of immune tolerance induction therapy (ITI) and emicizumab prophylaxis may provide additional benefits, but coagulation potential during this treatment remains unknown. We assessed coagulation potentials in simulated ITI models in vitro using modified-clot waveform analysis. Factor (F)VIII-deficient plasma preincubated with anti-A2 and anti-C2 monoclonal antibodies was reacted with emicizumab (50 µg/mL) (emicizumab–HA–plasma), then spiking bypassing agents (BPAs): activated prothrombin complex concentrates (aPCC 1.3 IU/mL; 50 IU/kg), recombinant factor (rF)VIIa (2.2 µg/mL; 90 µg/kg), and FVIIa/FX (1.5 µg/mL; 60 µg/kg), and/or FVIII (100, 200 IU/dL). Coagulation potentials in emicizumab–HA–plasma (10 BU/mL) remained within the normal range when BPA and FVIII were both present. In emicizumab–HA–plasma (1 BU/mL) with BPA and FVIII (200 IU/dL), they were near or beyond the normal range, but those with a half concentration of rFVIIa based on the half-life in blood were within the normal range. In samples without inhibitor, coagulation potentials with combined BPA and FVIII were far beyond the normal range but with FVIII (100 IU/dL) and rFVIIa at half concentration they remained within the normal range. These results may provide information on the feasibility of concurrent ITI under emicizumab prophylaxis.Keywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology (18K07885)
This publication has 41 references indexed in Scilit:
- Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor ActivityPLOS ONE, 2013
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A modelNature Medicine, 2012
- The principal results of the International Immune Tolerance Study: a randomized dose comparisonBlood, 2012
- Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high‐responding inhibitorsJournal of Thrombosis and Haemostasis, 2009
- Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitorsHaemophilia, 2009
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaThe New England Journal of Medicine, 2007
- Current use of by‐passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitorsHaemophilia, 2006
- Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish RegistryHaemophilia, 2001
- Induction of Immune Tolerance in Haemophilia A Inhibitor Patients by the ‘Bonn Protocol’: Predictive Parameter for Therapy Duration and OutcomeVox Sanguinis, 1999
- Tolerance induction using the Malmö treatment model 1982–1995Haemophilia, 1999